Jan 20 (Reuters) - Global drugmakers are ramping up U.S. manufacturing and stockpiling inventory as the Trump administration considers a 100% tariff on imported branded and patented medicines.
TSMC controls 68% of global semiconductor revenue, far ahead of Samsung's 8%. Market concentration poses both risks and opportunities for semiconductor investors. TSMC's advanced manufacturing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results